According to the World Cancer Research Fund International, 2,088,849 new cases of breast cancer were recorded around the world. As per the statistics, Belgium recorded the highest rate of breast cancer worldwide. This form of cancer is mostly prevalent among women, and it is felt as a lump in the breasts. In recent years, most of the cases have been diagnosed in developing and under-developed countries. The increasing incidence of breast cancer has, in turn, boosted the sales of breast biopsy devices globally.

Moreover, the advent of the liquid biopsy technique has amplified the adoption of breast biopsy devices. Liquid biopsy, or the analysis of circulating tumor deoxyribonucleic acid (ctDNA), is a low-risk and minimally-invasive process of detecting breast cancer.  This technique is used to analyze the genetic profile related to cancer, detect cancer tumors, and record the response of the patient to the therapy over a period. It is easier to diagnose cancer through this technique due to the release of DNA after the proliferation and death of cancer cells and their entry into the circulatory system.

The advent of new technologies has led to the introduction of new devices by companies like Danaher Corporation, Medtronic plc, Cook Medical LLC, Planmed Oy, Argon Medical Devices Inc., Scion Medical Technologies LLC, Hologic Inc., Becton, Dickinson and Company, and Sterylab S.R.L. Among these, Sterylab S.R.L. and Danaher Corporation only offer breast biopsy devices, namely CYTOMAT and MAMMOTOME, respectively. Whereas, Hologic Inc. provides breast biopsy devices and breast biopsy systems integrated 

with imaging modalities, such as the Affirm breast biopsy guidance system, Hologic Brevera ATEC, and Affirm prone EVIVA.

Geographically, North America emerged as the largest breast biopsy devices market in the past, wherein the U.S. generated the higher revenue. The increasing usage of such devices in the U.S. can be credited to the surging prevalence of breast cancer, booming aging population, expanding private healthcare sector, soaring healthcare expenditure, growing economy, and burgeoning number of research and development (R&D) studies in the medical sector. Most of the R&D investments in the country are made by pharmaceutical and biotechnology companies, research institutions, voluntary healthcare associations, professional societies, and federal, state, and local governments.

According to P&S Intelligence, the Asia-Pacific (APAC) region will record the fastest growth in the volume of breast biopsy procedures in the foreseeable future. This can be ascribed to the growing elderly population, soaring awareness regarding breast cancer and its burgeoning cases, increasing R&D on breast biopsy devices, and escalating per capita income and healthcare expenditure. Furthermore, Europe will record a significant rise in the demand for the associated devices due to almost the same reasons.

Thus, the growing prevalence of breast cancer and increasing R&D activities will fuel the deployment of breast biopsy devices in healthcare settings.